LncRNA MIR4435‐2HG functions as a ceRNA against miR‐125a‐5p and promotes neuroglioma development by upregulating TAZ

Abstract

Glioma is the most common primary central nervous system tumor, accounting for more than half of all primary intracranial tumors. 1 According to the World Health Organization (WHO) classification scheme, gliomas can be divided into four types: mixed glioma, neuroepithelial tumor, gliomatosis cerebri, and neuroglioma. 2 The transcription coactivator TAZ, which contains 400 amino acids, is one of the most important downstream effectors of the mammalian Hippo pathway. Its structure consists of a transcriptional-enhanced associate domain (TEAD)-binding region (TB), a WW region, a curly helix structure, a transcription activation region, and a PDZ motif at the C-terminus. 3,4 TAZ is involved in the transcriptional co-activation of downstream target factors, and the regulation of cell proliferation, apoptosis, and migration. 5,6 In recent years, it has been found that the expression of TAZ in gastric cancer, non-small

Biological Roles and Pathogenic Mechanisms of LncRNA MIR4435-2HG in Cancer: A Comprehensive Review

“…Additionally, it has been confirmed through research that MIR4435-2HG has the ability to activate the Wnt/β-catenin signaling pathway by suppressing the expression of desmoplakin (DSP), thus promoting the growth and metastasis of gastric cancer [12]. Moreover, it has been discovered by scientists that MIR4435-2HG can boost the expression of downstream genes in the Wnt signaling pathway, including β-catenin, c-Myc, and cyclin D [42]. By reducing the presence of MIR4435-2HG, the Wnt/β-catenin signaling pathway can be deactivated, leading to the inhibition of lung cancer and breast cancer cell proliferation and migration [9,36].…”

“…Experimental findings have demonstrated that the suppression of MIR4435-2HG can impede the growth and invasion of glioma cells, thereby hindering the progression of tumors in vivo [41]. Another set of experimental outcomes suggests that MIR4435-2HG can modulate the expression of TAZ by functioning as a sponge for miR-125a-5p, thus fostering the advancement of glioma [42]. Additionally, MIR4435-2HG might also enhance the expression of CD44 by absorbing miR-125a-5p and miR-125b-5p, impacting EMT and the TNF-α signaling pathway [43].…”

Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders

“…The expression level of TAZ was upregulated in the brain tissue of glioma patients. Shen et al indicated that the expression of MIR4435-2HG was positively correlated with TAZ expression, while miR-125a-5p expression was negatively correlated with TAZ expression in the brain tissue (Table 1) [61].…”